用于Vivo神经记录的 Ti₃C₂ MXene 微电极阵列的制造

Executive Industry Relevance

This protocol enables scalable fabrication of flexible microelectrode arrays using Ti₃C₂ MXene, addressing key barriers in neural interface development such as high impedance and mechanical mismatch with brain tissue. By leveraging MXene’s high conductivity and processability in aqueous dispersions, the method supports reliable in vivo electrocorticography recording with clear physiological signal detection. This advances discovery-stage target validation and mechanistic de-risking in neurotechnology pipelines by providing a reproducible platform for high-fidelity neural signal acquisition.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses through precise detection of cortical UP and DOWN states and associated brain rhythms.
• Operational Value: Provides stable, low-impedance electrodes that reduce signal noise and improve reproducibility in neural activity measurements.
• Predictive Confidence: Supports biomarker-linked functional readouts (e.g., slow oscillation modulation) for target engagement assessment in preclinical models.

Screening & Assay Development

• Scientific Value: Delivers quantitative, amplitude-resolved electrocorticography signals (~1 mV) enabling dose-response and compound effect screening.
• Operational Value: Yields reproducible microelectrode arrays with consistent impedance and signal-to-noise ratios across fabrication batches.
• Assay Readiness: Compatible with downstream workflows requiring chronic or acute neural interface integration in freely moving or anesthetized models.

Translational & Preclinical Research

• Translational Continuity: Bridges discovery neural recordings to preclinical validation by enabling chronic implantation feasibility studies.
• Mechanistic De-risking: Allows observation of brain state-dependent power shifts (e.g., beta/gamma amplification during UP states) linked to pharmacological interventions.
• Disease-Relevant System: Applicable to models of neurological injury or disease where cortical dynamics are altered (e.g., TBI, epilepsy).

Pipeline & Workflow Integration

The method fits within the discovery-to-preclinical continuum, supporting early hypothesis testing via neural signal acquisition and enabling assay-ready platforms for compound screening and target validation.

• Discovery Biology: Facilitates pathway clarification and network-level dynamics monitoring through spectral analysis of slow oscillations and gamma bands.
• Screening: Produces standardized electrode arrays suitable for high-throughput evaluation of neuromodulatory compounds.
• Analytics: Generates quantifiable outputs including amplitude, power spectra, and band-specific modulation (1–30 Hz, 40–120 Hz) for comparative condition analysis.
• Translational Research: Supports continuity from acute recording to chronic implant evaluation via flexible, biocompatible MXene-Parylene-C architecture.
• Enterprise Reuse: Adaptable to other conductive inks and geometries, enabling platform reuse across multiple neurotechnology projects.

Operational & Enterprise Impact

• Scientific Value: Enhances predictive confidence by reducing mechanistic ambiguity in neural circuit function through high-fidelity, low-noise recording.
• Operational Value: Ensures standardization and scalability via solution-based processing and photolithographic patterning.
• Strategic Value: Improves go/no-go decisions by enabling early detection of target-mediated neural effects, reducing late-stage failure risk.
• Portfolio Impact: Supports risk-adjusted prioritization of neurotherapeutics based on objective electrophysiological biomarkers.

Implementation Considerations

• Requires expertise in microfabrication, photolithography, and nanomaterial handling.
• Depends on access to electron beam evaporators, centrifuges, profilometers, and wet etching stations.
• Necessitates cross-team standardization between materials science, neuroscience, and engineering groups.
• Involves adaptation considerations when extending to other conductive inks or substrate materials.
• Involves practical limitations including use of hazardous chemicals (e.g., HF-derived etchants, photoresist strippers) requiring strict PPE and waste protocols.

Biopharma FAQs